Compare Mesoblast Limited (MESO) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Wynn Resorts, Limited — how do they compare? Mesoblast Limited trades at $16.23 (market cap $2.17B), while Wynn Resorts, Limited trades at $95.24 (market cap $9.93B). The key difference: Wynn Resorts, Limited is far larger — about 4.6× Mesoblast Limited's market cap, and Wynn Resorts, Limited pays a 1.05% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WYNN | |
|---|---|---|
Market Cap | $2.17B | $9.93B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $133.34 |
52-Week Low | $12.88 | $94.78 |
Enterprise Value | $2.17B | $20.29B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Wynn Resorts (WYNN) trades at $95.61, down 1.07% today, with a bearish technical signal and mixed earnings history including three consecutive quarterly misses. The company maintains strong revenue growth from $3.8B in 2022 to $7.1B in 2025, though net margins have compressed from 11.17% to 4.58% over the same period. Recent news highlights Q1 2026 earnings beating estimates with $1.25 EPS (Zacks Investment Research, May 7, 2026), while long-term debt remains elevated at $10.50B.
Analyst consensus is bullish with a $135.50 price target (64% buy ratings), but risks include high leverage, margin pressure from Macau competition, and geopolitical challenges for the UAE expansion. The stock offers 42% upside to consensus target if operational execution improves, though investors face volatility from earnings inconsistency and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
